Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Daiichi Sankyo’s Enhertu, Novartis’ Beovu, Novo’s Ozempic OK’ed for Listing on May 20
Japan’s all-important reimbursement policy panel on May 13 approved the listing of 18 drugs on May 20 including Daiichi Sankyo’s cancer drug Enhertu (trastuzumab deruxtecan) and Novartis’ wet age-related macular degeneration (AMD) treatment Beovu (brolucizumab). The Central Social Insurance Medical…
To read the full story
Related Article
- Novartis Launches AMD Drug Beovu in Japan
May 26, 2020
- Daiichi Sankyo’s Enhertu Hits Japan Market for Breast Cancer
May 26, 2020
- As Beovu Debut Nears, Novartis Set to Push Longer Dosing Interval, Pivotal Data in Battle against Eylea
May 22, 2020
- Nippon Shinyaku’s DMD Drug Now Available in Japan; AZ’s Lokelma, Ono’s Velexbru Too
May 21, 2020
- Japan OKs Enhertu, 3 Sakigake Drugs, Beovu, Latuda, and More
March 26, 2020
- Japan OKs Novo’s Single-Dose Pen Devices for List-Pending Ozempic
March 16, 2020
REGULATORY
- Zepbound’s OSA Indication Up for Panel Review on April 24
April 20, 2026
- LDP Pharma Project Team to Compile Roadmap Proposals after Industry Hearings
April 17, 2026
- DPJ Leader to Urge Drug Price Hikes, “Freeze” on Off-Year Revisions
April 17, 2026
- War-Linked Supply Impact Cases Climb to 34 as Japan Steps Up Response
April 17, 2026
- Meiji Pharma Chair Prods Drug Price Hikes as War Drives Up Costs: Diet
April 17, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…